Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

China’s National Health Commission (NHC) issued the Work Plan to Accelerate the Provision of High‑Quality...

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026

China’s Center for Drug Evaluation (CDE) announced on September 7, 2026 the selection of the...

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026

According to Yicai, the 2026 national healthcare security negotiations will officially kick off in Beijing...

Policy / Regulatory

NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three‑Agency Regulatory Adjustment

Fineline Cube Sep 3, 2026

The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the...

Policy / Regulatory

NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms

Fineline Cube Sep 3, 2026

The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy...

Policy / Regulatory

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

Fineline Cube Sep 2, 2026

China’s National Healthcare Security Administration (NHSA) officially released the Version 3.0 Grouping Scheme for Diagnosis-Related...

Policy / Regulatory

NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors

Fineline Cube Sep 2, 2026

The National Medical Products Administration (NMPA) issued the Announcement on Further Strengthening the Management of...

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) issued the...

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026

China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Fineline Cube Sep 1, 2026

President Donald Trump announced new agreements with nine pharmaceutical companies to lower prescription drug prices...

Policy / Regulatory

China NPC Passes Medical Security Law, Establishing Multi‑Tier Medical Insurance Framework Effective 2027

Fineline Cube Sep 1, 2026

The Standing Committee of the National People’s Congress (NPC) voted to pass the Medical Security...

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026

GluBio Pharmaceuticals announced that GLB‑005, its self‑developed widely interspaced zinc finger (WIZ) molecular glue degrader...

Policy / Regulatory

China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP

Fineline Cube Aug 28, 2026

The National Health Commission of China (NHC) released the Statistical Bulletin on Health Development in...

Policy / Regulatory

NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change

Fineline Cube Aug 27, 2026

The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales...

Policy / Regulatory

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Fineline Cube Aug 27, 2026

The National Healthcare Security Administration (NHSA) issued the Guiding Opinions on Improving the Payment Management...

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026

China’s National Health Commission (NHC), together with the National Administration of Traditional Chinese Medicine and...

Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026

China’s National Medical Products Administration (NMPA) issued the Catalog of Reference Listed Drugs for Generic...

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026

China’s National Health Commission (NHC), together with the National Administration of Traditional Chinese Medicine and...

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released work...

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026

The U.S. Food and Drug Administration (FDA) issued a discussion paper on considerations for the...

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three‑Agency Regulatory Adjustment

NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

China NPC Passes Medical Security Law, Establishing Multi‑Tier Medical Insurance Framework Effective 2027

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP

NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

You Missed

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins